Klempner, S. J., Sonbol, B. B., Wainberg, Z. A., Uronis, H. E., Chiu, V. K., Scott, A. J., … Ajani, J. A. (2023). A phase 2 study (DisTinGuish) of DKN-01 in combination with tislelizumab plus chemotherapy as first-line (1L) therapy in patients with advanced gastric or GEJ adenocarcinoma (GEA). In JOURNAL OF CLINICAL ONCOLOGY (Vol. 41).

Klempner, Samuel J., Bassam Bassam Sonbol, Zev A. Wainberg, Hope Elizabeth Uronis, Vi Kien Chiu, Aaron James Scott, Syma Iqbal, et al. “A phase 2 study (DisTinGuish) of DKN-01 in combination with tislelizumab plus chemotherapy as first-line (1L) therapy in patients with advanced gastric or GEJ adenocarcinoma (GEA).” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 41, 2023.

Klempner SJ, Sonbol BB, Wainberg ZA, Uronis HE, Chiu VK, Scott AJ, et al. A phase 2 study (DisTinGuish) of DKN-01 in combination with tislelizumab plus chemotherapy as first-line (1L) therapy in patients with advanced gastric or GEJ adenocarcinoma (GEA). In: JOURNAL OF CLINICAL ONCOLOGY. 2023.

Klempner, Samuel J., et al. “A phase 2 study (DisTinGuish) of DKN-01 in combination with tislelizumab plus chemotherapy as first-line (1L) therapy in patients with advanced gastric or GEJ adenocarcinoma (GEA).” JOURNAL OF CLINICAL ONCOLOGY, vol. 41, no. 16, 2023.

Klempner SJ, Sonbol BB, Wainberg ZA, Uronis HE, Chiu VK, Scott AJ, Iqbal S, Tejani MA, Stilian MC, Thoma M, Kagey M, Baum J, Sirard CA, Altura RA, Ajani JA. A phase 2 study (DisTinGuish) of DKN-01 in combination with tislelizumab plus chemotherapy as first-line (1L) therapy in patients with advanced gastric or GEJ adenocarcinoma (GEA). JOURNAL OF CLINICAL ONCOLOGY. 2023.